Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia

被引：3

作者：

Li, Xueyao ^{[1
]}

Tong, Xiuzhen ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, 58 Second Zhongshan Rd, Guangzhou 510080, Peoples R China

来源：

CLINICAL INTERVENTIONS IN AGING | 2023年 / 18卷

关键词：

detection method; risk-stratification marker; postremission decisions; personalized medicine; HEMATOPOIETIC-CELL TRANSPLANTATION; CLONAL HEMATOPOIESIS; PROGNOSTIC RELEVANCE; AML; MUTATIONS; AZACITIDINE; THERAPY; RISK; DECITABINE; MANAGEMENT;

D O I：

10.2147/CIA.S409308

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

There is overwhelming evidence indicating that the use of measurable residual disease (MRD) as a biomarker provides critical prognostic information and that MRD may have a role in directing postremission decisions. There are a variety of assays for MRD assessment, such as multiparameter flow cytometry and molecular assessment of MRD, which present different characteristics in patients older than 60 years of age. Due to multiple reasons related to age, the progress of older adult AML patients is rarely investigated, especially with respect to MRD. In this review, we will clarify the characteristics of different assays for assessing MRD, focusing on its role as a risk-stratification biomarker to predict prognostic information and its role in optimal postremission therapy among older adult AML patients. These characteristics also provide guidance regarding the potential to apply personalized medicine in older adult AML patients.

引用

页码：921 / 931

页数：11

共 50 条

[31] Universal monitoring of minimal residual disease in acute myeloid leukemia [J].

Coustan-Smith, Elaine ;

Song, Guangchun ;

Shurtleff, Sheila ;

Yeoh, Allen Eng-Juh ;

Chng, Wee Joo ;

Chen, Siew Peng ;

Rubnitz, Jeffrey E. ;

Pui, Ching-Hon ;

Downing, James R. ;

Campana, Dario .

JCI INSIGHT, 2018, 3 (09)

[32] Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial [J].

Simoes, Catia ;

Paiva, Bruno ;

Martinez-Cuadron, David ;

Bergua, Juan-Miguel ;

Vives, Susana ;

Algarra, Lorenzo ;

Tormo, Mar ;

Martinez, Pilar ;

Serrano, Josefina ;

Herrera, Pilar ;

Ramos, Fernando ;

Salamero, Olga ;

Lavilla, Esperanza ;

Gil, Cristina ;

Lopez, Jose-Luis ;

Vidriales, Maria-Belen ;

Labrador, Jorge ;

Falantes, Jose-Francisco ;

Sayas, Maria-Jose ;

Ayala, Rosa ;

Martinez-Lopez, Joaquin ;

Villar, Sara ;

Calasanz, Maria-Jose ;

Prosper, Felipe ;

San-Miguel, Jesus F. ;

Sanz, Miguel Angel ;

Montesinos, Pau .

BLOOD ADVANCES, 2021, 5 (03) :760-770

[33] Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time? [J].

El Chaer, Firas ;

Perissinotti, Anthony J. ;

Loghavi, Sanam ;

Zeidan, Amer M. .

LEUKEMIA, 2025, 39 (01) :1-7

[34] Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia [J].

Christopher, Mary R. ;

Nawas, Mariam T. ;

Reagan, John L. .

BONE MARROW TRANSPLANTATION, 2025, 60 (02) :135-143

[35] Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia [J].

Mannelli, Francesco ;

Piccini, Matteo ;

Bencini, Sara ;

Gianfaldoni, Giacomo ;

Peruzzi, Benedetta ;

Caporale, Roberto ;

Scappini, Barbara ;

Fasano, Laura ;

Quinti, Elisa ;

Ciolli, Gaia ;

Pasquini, Andrea ;

Crupi, Francesca ;

Pilerci, Sofia ;

Pancani, Fabiana ;

Signori, Leonardo ;

Tarantino, Danilo ;

Maccari, Chiara ;

Paradiso, Vivian ;

Annunziato, Francesco ;

Guglielmelli, Paola ;

Vannucchi, Alessandro M. .

HAEMATOLOGICA, 2024, 109 (01) :60-71

[36] Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection [J].

Rajsri, Kritika Srinivasan ;

Roy, Nainita ;

Chakraborty, Sohini .

CANCERS, 2023, 15 (10)

[37] Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia [J].

Stahl, Maximilian ;

Derkach, Andriy ;

Farnoud, Noushin ;

Bewersdorf, Jan Philipp ;

Robinson, Troy ;

Famulare, Christopher ;

Cho, Christina ;

Devlin, Sean ;

Menghrajani, Kamal ;

Patel, Minal A. ;

Cai, Sheng F. ;

Miles, Linde A. ;

Bowman, Robert L. ;

Geyer, Mark B. ;

Dunbar, Andrew ;

Epstein-Peterson, Zachary D. ;

McGovern, Erin ;

Schulman, Jessica ;

Glass, Jacob L. ;

Taylor, Justin ;

Viny, Aaron D. ;

Stein, Eytan M. ;

Getta, Bartlomiej ;

Arcila, Maria E. ;

Gao, Qi ;

Barker, Juliet ;

Shaffer, Brian C. ;

Papadopoulos, Esperanza B. ;

Gyurkocza, Boglarka ;

Perales, Miguel-Angel ;

Abdel-Wahab, Omar ;

Levine, Ross L. ;

Giralt, Sergio A. ;

Zhang, Yanming ;

Xiao, Wenbin ;

Pai, Nidhi ;

Papaemmanuil, Elli ;

Tallman, Martin S. ;

Roshal, Mikhail ;

Goldberg, Aaron D. .

AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (01) :79-89

[38] How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? [J].

Short, Nicholas J. ;

Ravandi, Farhad .

HAEMATOLOGICA, 2019, 104 (08) :1532-1541

[39] Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible? [J].

Brooimans, Rik A. ;

van der Velden, Vincent H. J. ;

Boeckx, Nancy ;

Slomp, Jennita ;

Preijers, Frank ;

te Marvelde, Jeroen G. ;

Van, Ngoc M. ;

Heijs, Antoinette ;

Huys, Erik ;

van der Holt, Bronno ;

de Greef, Georgine E. ;

Kelder, Angele ;

Schuurhuis, Gerrit Jan .

LEUKEMIA RESEARCH, 2019, 76 :39-47

[40] Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors [J].

Ozdemir, Zehra Narli ;

Sahin, Ugur ;

Dalva, Klara ;

Baltaci, Mehmet Akif ;

Uslu, Atilla ;

Ozturk, Cemaleddin ;

Seval, Guldane Cengiz ;

Toprak, Selami Kocak ;

Yuksel, Meltem Kurt ;

Topcuoglu, Pervin ;

Arslan, Onder ;

Ozcan, Muhit ;

Beksac, Meral ;

Ilhan, Osman ;

Gurman, Gunhan ;

Bozdag, Sinem Civriz .

TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (02) :111-118

← 1 2 3 4 5 →